Trial · NCT03292406
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12 | CD11301 Gel 0.06% | Complete Response | 0 | Participants | |
| Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12 | CD11301 Gel 0.03% | Complete Response | 2 | Participants | |
| Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12 | Placebo | Complete Response | 0 | Participants | |
| Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12 | CD11301 Gel 0.06% | Partial Response | 4 | Participants | |
| Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12 | CD11301 Gel 0.03% | Partial Response | 5 | Participants | |
| Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12 | Placebo | Partial Response | 1 | Participants | |
| Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12 | CD11301 Gel 0.06% | Complete Response | 0 | Participants | |
| Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12 | CD11301 Gel 0.03% | Complete Response | 0 | Participants | |
| Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12 | Placebo | Complete Response | 0 | Participants | |
| Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12 | CD11301 Gel 0.06% | Partial Response | 6 | Participants | |
| Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12 | CD11301 Gel 0.03% | Partial Response | 4 | Participants | |
| Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12 | Placebo | Partial Response | 2 | Participants | |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | CD11301 Gel 0.06% | 25th (95% CI) | 169 | 95% Confidence Interval 84.0 to 169.0 | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | CD11301 Gel 0.03% | 25th (95% CI) | 85 | 95% Confidence Interval 83.0 to 174.0 | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | Placebo | 25th (95% CI) | NA | 95% Confidence Interval 85.0 to NA | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | CD11301 Gel 0.06% | 50th (95% CI) | 197 | 95% Confidence Interval 169.0 to 257 | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | CD11301 Gel 0.03% | 50th (95% CI) | NA | 95% Confidence Interval 169.0 to NA | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | Placebo | 50th (95% CI) | NA | 95% Confidence Interval NA to NA | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | CD11301 Gel 0.06% | 75th (95% CI) | 257 | 95% Confidence Interval 197.0 to 257 | Days |
| Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score | CD11301 Gel 0.03% | 75th (95% CI) | NA | 95% Confidence Interval NA to NA | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03292406/results